The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology ...

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in ...

Asbestos workers in the state of Louisiana who have been diagnosed with mesothelioma cancer or asbestos lung cancer may be ...

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...